4//SEC Filing
Chen Hongming 4
Accession 0001415889-21-005014
CIK 0001479419other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 8:06 PM ET
Size
7.7 KB
Accession
0001415889-21-005014
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Sale
Common Stock
2021-10-27$1.82/sh−21,051$38,313→ 204,515 total - Sale
Common Stock
2021-10-26$1.80/sh−9,449$17,008→ 225,566 total
Footnotes (5)
- [F1]This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F3]Includes 61,166 unvested RSUs.
- [F4]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.84, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Documents
Issuer
Kala Pharmaceuticals, Inc.
CIK 0001479419
Entity typeother
Related Parties
1- filerCIK 0001710697
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 8:06 PM ET
- Size
- 7.7 KB